Boston Scientific reported fourth-quarter net sales of $5.286 billion, up 15.9% on a reported basis versus year-ago levels, surpassing its guidance range of 14.5%–16.5%. Organic sales growth reached 12.7%, beating the 11%–13% forecast. GAAP net income attributable to common stockholders was $672 million, or $0.45 per share, compared to $566 million, or $0.38 per share, a year earlier. Adjusted earnings per share of $0.80 topped the prior-year adjusted result of $0.70 and the guidance range of $0.77–$0.79. Strength was broad-based, with Cardiovascular up 18.2% reported and MedSurg up 11.7% reported, while the U.S. saw 17.0% sales growth and Asia-Pacific 15.2%.

Despite the robust fourth-quarter performance, management forecast modest full-year 2026 revenue growth below Street expectations and profit margins slightly under consensus. Coupled with discontinuation of the ACURATE neo2 and Prime Aortic Valve Systems earlier this year, the conservative outlook prompted an early-morning share decline of over 11%. Investors highlighted the company's caution on supply-chain costs, foreign currency headwinds and continued investment in research and development as factors tempering near-term margins.

The electrophysiology segment fell short of internal targets in Q4, with pulsed field ablation catheter sales underperforming growth forecasts by approximately $30 million. Management attributed the shortfall to slower adoption of the new FARAPOINT™ PFA catheter in certain U.S. markets and extended FDA review timelines for accessory mapping technologies. Ongoing clinical trials—OPTIMIZE and SIMPLAAFY—are expected to read out later this year and could accelerate device uptake if results are favorable.

Boston Scientific secured FDA approval and CE marking for multiple devices, including the FARAPOINT™ PFA catheter and the TheraSphere 360™ Y-90 Management Platform, expanding its interventional oncology and electrophysiology franchises. The company initiated launches of the SEISMIQ™ Intravascular Lithotripsy System in the U.S. and completed enrollment in global trials for complex calcified artery treatments. Strategic acquisitions announced include agreements to acquire Penumbra, Inc., for neurovascular and thrombectomy solutions, and Valencia Technologies for the eCoin® tibial nerve stimulation system, reflecting a commitment to diversify revenue streams and bolster its neurostimulation portfolio.